Hill staff gets briefed on implications of Trump’s drug pricing plan

Taking stock of the drug industry, from the lab to the medicine chest

September 15, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

J. Scott Applewhite/AP STAT+ | Hill staff gets briefed on implications of Trump's drug pricing plan Experts from right- and left-leaning think tanks join Congressional staff to discuss Trump's most-favored nation drug pricing plan. By Daniel Payne Opinion: 9 answers to burning questions about pharmaceutical ads Why does the U.S. allow prescription drug ads? Can they be banned? And other big questions on direct-to-consumer pharma ads, answered. By Aaron S. Kesselheim and Katelyn K. Jetelina Opinion: The Trump admin's cruel disbanding of the Pediatric Brain Tumor Consortium Because of the disbanding of the PBTC, children with rare brain cancers may be denied new and promising treatments. By Josie Glausiusz Adobe STAT+ | Inside the hospital 'war rooms' bracing for Medicaid cuts Hospitals nationwide prepare for nearly $1T in Medicaid cuts, weighing service reductions, consolidation, and new tech as patient care hangs in the balance. By Daniel Payne

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser